health · HHS-NIH11
NIAMS Clinical Trial Implementation Cooperative Agreement
National Institutes of Health · PAR-28-031
Expected Awards
4
Deadline
TBD
GRANTQUICK SUMMARYPlain-English Overview
NIAMS Clinical Trial Implementation Cooperative Agreement. National Institutes of Health. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the Clinical Trial Cooperative Agreement Program within the mission areas of the institute.... at least $250,000 per award; ~4 awards expected.
Who Should Apply
Other eligible entities, State governments, Independent school districts, Public universities/colleges, Private universities/colleges (+10 more)
Who Should NOT Apply
Organizations not matching the eligible applicant types listed above
Key Requirements (Plain English)
- •Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U
💡 GrantQuick Tip
Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.
Competitiveness: Very high — extremely limited awards available
What This Grant Funds
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the Clinical Trial Cooperative Agreement Program within the mission areas of the institute. This Notice of Funding Opportunity (NOFO) solicits cooperative agreement applications for implementation of investigator-initiated, single or multi-site, interventional clinical trials (all trial phases). Investigators who have completed all necessary preparation (e.g., the trial design, protocol synopsis, data analysis plan, etc.) through other means may apply for a NIAMS Cooperative Agreement Clinical Trial. The first phase is designed to allow the investigators to prepare the final aspects needed to start the trial, (e.g., establishing the single IRB (sIRB), contracts and reliance agreements with sites, hiring of staff, etc.). Transition to the second phase to begin the trial is dependent upon completion of the phase 1 milestones proposed by the investigator and approved by NIAMS. Phase 1 projects that meet their milestones will be administratively considered by NIAMS and prioritized for transition to the second phase. NIAMS expects trials to be hypothesis-driven and have the potential for high clinical impact within the research mission of NIAMS.
Who Can Apply
Eligible Applicant Types
Funding Details
- Minimum Award
- $250K
- Expected Number of Awards
- 4
- Cost Sharing Required?
- No
- Funding Instrument
- cooperative_agreement
Key Dates
Agency Contact
National Institute of Arthritis and Musculoskeletal and Skin Diseases Please contact via e-mail.
NIAMS_NOFOs@mail.nih.govReady to apply?
View the full NOFO and submit your application on Grants.gov